Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia
Activated protein C (APC) is a plasma serine protease with antithrombotic and cytoprotective functions. Here, the authors develop a monoclonal antibody that specifically inhibits APC’s anticoagulant function without compromising its cytoprotective function, and shows efficacy in animal models.
Guardado en:
Autores principales: | Xiao-Yan Zhao, Andreas Wilmen, Dongli Wang, Xinquan Wang, Maxine Bauzon, Ji-Yun Kim, Lars Linden, Liang Li, Ursula Egner, Tobias Marquardt, Dieter Moosmayer, Jan Tebbe, Julian Marius Glück, Philipp Ellinger, Kirk McLean, Shujun Yuan, Subramanian Yegneswaran, Xiaoqiao Jiang, Vince Evans, Jian-Ming Gu, Doug Schneider, Ying Zhu, Yifan Xu, Cornell Mallari, Ashley Hesslein, Yan Wang, Nicole Schmidt, Katrin Gutberlet, Christine Ruehl-Fehlert, Alexius Freyberger, Terry Hermiston, Chandra Patel, Derek Sim, Laurent O. Mosnier, Volker Laux |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9ba7c3d64bcb4b03984dbf3b38cd94db |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The management of hemophilia in elderly patients
por: Massimo Franchini, et al.
Publicado: (2007) -
Sports and Children with Hemophilia: Current Trends
por: Lorenzo Moretti, et al.
Publicado: (2021) -
Skull hemophilia pseudotumor: A case report
por: Lin Kunzhe, et al.
Publicado: (2021) -
Recent Advances in the Treatment of Hemophilia: A Review
por: Marchesini E, et al.
Publicado: (2021) -
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Haowei (Linda) Sun, et al.
Publicado: (2021)